Deals: Page 65
-
Celgene bolsters cancer pipeline with another big biotech deal
Cambridge biotech Jounce Therapeutics will receive $225 million upfront plus a hefty $2.3 billion in potential milestone payments tied to its immuno-oncology candidates.
By Edwin Lopez • July 19, 2016 -
Teva raises $15 billion through bond sale
Proceeds from the sale will help fund Teva's $40.5 billion acquisition of Allergan's generics division.
By Nicole Gray • July 19, 2016 -
High-profile VC firm hires former Merck exec as chief medical officer
Flagship Ventures has been active in supporting biotech firms coming out of Cambridge, MA.
By Nicole Gray • July 14, 2016 -
Teva, Allergan generics deal to close 'at any time now'
Underscoring Teva's confidence in winning final U.S. approval for the deal, the Israeli drugmaker also put out rosy revenue projections through 2019.
By Edwin Lopez • July 13, 2016 -
Nichi-Iko expands into US with $736 million Sagent buy
Currently dependent on the Japanese market, Nichi-Iko has designs to become a generics player internationally.
By Nicole Gray • July 12, 2016 -
Medicines Patent Pool expands access to HIV, hepatitis C drugs with new deals
Four of the licensing agreements with the UN-backed health group covered Bristol-Myers Squibb's Daklinza.
By Nicole Gray • July 11, 2016 -
Moderna and Vertex partner to target cystic fibrosis with RNA therapies
Vertex will pay $40 million upfront to Moderna, with the potential for another $275 million in milestone payments.
By Nicole Gray • July 7, 2016 -
Valeant mulling sale of dermatology assets to Spanish Almirall: report
Although Valeant has made some steps toward recovering from a disastrous first quarter, the company still faces a substantial debt load.
By Nicole Gray • July 6, 2016 -
Despite sluggish IPO market, biotechs continue to lead the way
Nine out of 12 venture-backed IPOs in the second quarter were for biotech firms, according to a new report.
By Nicole Gray • July 6, 2016 -
Sanofi, Army partner to hasten Zika vaccine trials
The Walter Reed Army Institute of Research will transfer its technology to Sanofi for Phase 2 testing and regulatory strategy.
By Edwin Lopez • July 6, 2016 -
Courtesy of Sanofi
Medivation enters takeover talks with Sanofi after rejecting new bid
But Sanofi will have company: Medivation said it had also agreed to open its books to a number of other interested parties.
By Ned Pagliarulo • July 5, 2016 -
Chinese biotech CStone raises $150 million in new financing
A former Sanofi exec will head up the new company, which aims to become a research leader in China.
By Nicole Gray • July 5, 2016 -
Bristol-Myers buys Cormorant Pharma, eyes cancer combo potential
While Bristol is on the hook for only $95 million in upfront and near-term payments, the deal could be worth over $500 million if all milestones are hit.
By Ned Pagliarulo • July 5, 2016 -
Pfizer makes bid for Bind after repayment woes
A demand for accelerated repayment on a $15 million loan led Bind to file for bankruptcy in May.
By Nicole Gray • July 5, 2016 -
AstraZeneca sells off dermatology drug rights to LEO Pharma
The British drugmaker also terminated a prior deal granting Valeant European rights to a psoriasis treatment, licensing those rights to LEO instead.
By Ned Pagliarulo • July 1, 2016 -
Boston startup secures $51.5 million in race for next-gen integrin technology
GlaxoSmithKline, Pfizer and AbbVie are among the backers betting integrin-pioneer Tim Springer's research will pay off.
By Edwin Lopez • June 30, 2016 -
Teva, Allergan sell off more drugs in quest for approval of generics deal
Mayne Pharma, an Australian company, will pay $652 million for 42 generic drugs currently held by the two companies.
By Nicole Gray • June 29, 2016 -
Dr. Reddy's breaks off marketing partnership with Glaxo
The Indian drugmaker plans to expand its presence in a number of emerging markets covered under the 2009 agreement.
By Nicole Gray • June 28, 2016 -
Novartis jumps into bi-specific antibody space with $150 million Xencor deal
The Swiss pharma giant will partner with Xencor to develop two bi-specific antibodies for treatment of blood cancers.
By Ned Pagliarulo • June 28, 2016 -
Courtesy of Sanofi
Sanofi, Boehringer trade business units in $25 billion swap
Under the agreement, Sanofi will get Boehringer's consumer healthcare business in return for sending its Merial animal-health unit to Boehringer.
By Ned Pagliarulo • June 27, 2016 -
Takeda hands back two developmental drugs to Amgen
Under a 2008 collaboration deal, Takeda was granted rights to 13 Amgen molecules in the Japanese market.
By Nicole Gray • June 27, 2016 -
Selecta Biosciences raises $70 million in IPO, forges ahead with gout drug
Selecta is the sixth Massachusetts-based biotech to go public this year.
By Nicole Gray • June 23, 2016 -
Celgene puts up $50 million to partner with four NCI cancer centers
The four high-profile centers have banded together to create a unified cancer research group
By Nicole Gray • June 23, 2016 -
Austin biotech Savara adds two lung drugs in deal for Serendex
Savara raised $20 million in March to advance its lead drug, an inhaled antibiotic, into Phase 3 testing.
By Nicole Gray • June 22, 2016 -
Teva, Allergan continue to shed assets with $586 million sale to Impax
The Israeli drugmaker has been selling off non-core drugs as it works to clear regulatory review for its $41 billion acquisition of Allergan's generics unit.
By Ned Pagliarulo • June 21, 2016
Previous
